Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Multiple Myeloma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Carcinoma, Non-Small-Cell Lung 6Neoplasm, Residual 3Neoplasm Metastasis 3Leukemia, Myeloid, Acute 3Neoplasms 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Smoldering Multiple Myeloma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Plasma Cell 1Nasopharyngeal Carcinoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Promyelocytic, Acute 1Leukemia, Plasma Cell 1

Interventions

Rituximab 313Cyclophosphamide 286fludarabine phosphate 213fludarabine 140ibrutinib 121Peripheral Blood Stem Cell Transplantation 116venetoclax 108Mycophenolic Acid 102obinutuzumab 88Lenalidomide 88Bendamustine Hydrochloride 87Whole-Body Irradiation 85Filgrastim 84Tacrolimus 78Cyclosporine 78Busulfan 70Melphalan 65Radiotherapy 63Antilymphocyte Serum 61Alemtuzumab 58Etoposide 56acalabrutinib 54Methotrexate 49ofatumumab 46idelalisib 38Cytarabine 33Chlorambucil 33zanubrutinib 31sargramostim 30Specimen Handling 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × Maintenance × Clear all
NCT04542824 2026-06-02

EPCOREâ„¢ NHL-3

Genmab

Phase 1/2 Active not recruiting
78 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT03847727 2020-01-18

Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia

Pirogov Russian National Research Medical University

Unknown
112 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡